NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug dose Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , April 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
-   New positive clinical and translational data for both lead agents -   Strong balance sheet with 2017 year-end cash and equivalents of $144.2 Million -   Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , March 14, 2018 (GLOBE NEWSWIRE) -- Immune Design
View HTML
Toggle Summary Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient population Objective response rate (ORR) for follicular lymphoma patients treated with G100 and pembrolizumab
View HTML
Toggle Summary Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , March 07, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report fourth quarter and year end 2017 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design to Present at Upcoming Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Calif. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that senior management will present at upcoming investor conferences.
View HTML
Toggle Summary Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/refractory and treatment-naïve patient populations Data presented at ASH 2017
View HTML
Toggle Summary Immune Design to Present at Jefferies 2017 London Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 London
View HTML
Toggle Summary Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced seven presentations at the upcoming Connective Tissue Oncology Society (CTOS) and the Society for Immunotherapy of
View HTML
Toggle Summary Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML